Series D · Biotech · Cambridge, United Kingdom · Founded 2015 · 51–100 employees
Artios Pharma is a pioneering clinical-stage biopharmaceutical company focused on developing next-generation DNA damage response (DDR) therapies for cancer treatment. The company has built an innovative pipeline including its lead ATR inhibitor alnodesertib and DNA polymerase theta inhibitor ART6043, both potential first-in-class treatments targeting hard-to-treat solid tumors. In November 2025, Artios raised an oversubscribed $115 million Series D to advance Phase 2 clinical trials in pancreatic, colorectal, and breast cancers. The company has demonstrated strong clinical signals with alnodesertib showing a 50% response rate in ATM-negative solid tumors and has strategic partnerships with Merck KGaA and Novartis.
No open roles listed right now.